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Abstract
Background:  Currently, there is much interest in measuring fractional exhaled nitric oxide
(FENO) in populations. We evaluated the reproducibility of FENO  in healthy subjects and
determined the number of subjects necessary to carry out a longitudinal survey of FENO in a
population containing smokers and non-smokers, based on the assessed reproducibility.
Methods: The reproducibility of FENO was examined in 18 healthy smokers and 21 non-smokers.
FENO was assessed once at 9 AM on five consecutive days; in the last day this measurement was
repeated at 2 PM. Respiratory symptoms and medical history were assessed by questionnaire. The
within- and between-session repeatability of FENO and log-transformed FENO was described. The
power of a longitudinal study based on a relative increase in FENO was estimated using a bilateral
t-test of the log-transformed FENO using the between-session variance of the assay.
Results: FENO  measurements were highly reproducible throughout the study. FENO  was
significantly higher in males than females regardless of smoking status. FENO was positively
associated with height (p < 0.001), gender (p < 0.034), smoking (p < 0.0001) and percent FEV1/FVC
(p < 0.001) but not with age (p = 0.987). The between-session standard deviation was roughly
constant on the log scale. Assuming the between-session standard deviation is equal to its
longitudinal equivalent, either 111 or 29 subjects would be necessary to achieve an 80% power in
detecting a 3% or a 10% increase in FENO respectively.
Conclusion: The good reproducibility of FENO is not influenced by gender or smoking habits. In
a well controlled, longitudinal study it should allow detecting even small increases in FENO with a
reasonable population size.
Background
Fractional exhaled nitric oxide (FENO) is now widely used
as a surrogate marker for eosinophilic airway inflamma-
tion [1]. Yet, several personal and environmental factors
including active or passive smoking may influence FENO
thus acting as causes of bias [2].
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Good reproducibility is an important precondition for
using a physiological test both for clinical and epidemio-
logical purposes [3]. While the variability and reproduci-
bility of FENO  have been evaluated in patients with
asthma, studies in healthy subjects usually excluded
smokers [4-7]. Since exposure to cigarette smoke
decreases FENO [8-13] a given instrumental or biological
variation will yield higher coefficients of variation if the
denominator is lower.
Currently, there is much interest in assessing longitudinal
changes in FENO levels in populations. Ensuring a low var-
iability and good reproducibility in this setting is critical
in distinguishing true biological changes from other
sources of variation. In this study, we examined the influ-
ence of smoking status and gender on the reproducibility
of FENO measurements in a group of healthy individuals.
Then, based on the reproducibility, we determined the
sample size necessary to carry out a longitudinal study on
the evolution of FENO, a matter on which there is virtually
no information in the literature.
Methods
Subjects and Protocol
Thirty-nine young subjects were recruited among clerks,
technicians, engineers, postgraduate students and medical
residents from the University of Nancy. There were 21
non-smokers (10 males and 11 females) and 18 smokers
(9 males and 9 females). The selection criteria were a neg-
ative history of respiratory symptoms and allergic diseases
(e.g. rhinitis, eczema), and normal spirometry. Subjects
with acute respiratory infection in the last 4 weeks were
excluded. None of the volunteers was taking any drug or
medication. All subjects gave informed consent and the
research protocol was approved by our local ethics in
medical research committee.
Subjects were approached a first day when a brief respira-
tory symptoms questionnaire was administered through a
face-to-face interview and pulmonary function tests were
performed. The questionnaire covered personal and
demographic information, past and present chest dis-
eases, respiratory symptoms and allergies, and past and
present smoking habits. After inclusion, six sessions of
three measurements were planned over one week. All sub-
jects had their FENO measured once on five consecutive
days, from Monday through Friday, between 09:00–10:00
h during visits 1, 2, 3 and 4; during the last visit FENO was
measured twice between 09:00–10:00 h and 14:00–15:00
h.
Spirometry was carried out in the sitting position, using
an electronic spirometer (Oscilolink, Datalink, Montepel-
lier, France). Forced vital capacity (FVC) and forced expir-
atory volume in one second (FEV1) were obtained by
having the subject expire forcefully after a maximal inspir-
atory maneuver. At least three forced expiratory maneu-
vers, satisfactory according to recommended criteria [14]
were recorded. The curve with the highest sum of FVC+
FEV1 was used for analysis. Curves with an FEV1/FVC ratio
of 80% or higher and a predicted [15] FEV1 ≥ 75% were
considered as normal.
FENO was measured according to the ATS/ERS recommen-
dations [16]. Measurements were done using a chemilu-
minescence analyzer (NIOX® 2.0 system; Aerocrine AB,
Solna, Sweden). The subject was in the sitting position
and exhaled against an oral pressure of 5 cm H20 – suffi-
cient to close the velum – at a flow rate of 50 mL/s. At each
session, three correctly performed exhalations were
recorded. Any exhalation which did not meet the ATS/ERS
requirements was rejected by the NIOX system and the
subject was asked to perform a new exhalation maneuver.
Calibrations were performed every 13 days according to
the standards of the manufacturer. Subjects avoided eat-
ing for 1 hour and smoking for 8 hours before testing.
Statistical analysis
Statistical analysis was performed using the Stata package
[17]. The Shapiro-Wilks test was used to check the nor-
mality and log-normality of the measurements. Repro-
ducibility of FENO  measurements was assessed by the
Bland Altman analysis [18]. Within-session repeatability
was assessed by plotting the difference between each of
the three measurements of a session and their session
mean against the session mean. This procedure generated
three data points by subject by session, thus yielding 702
data points (39 subjects × 3 measures by session × 6 ses-
sions = 702). Between-session repeatability was calculated
by plotting the difference between a mean session FENO
and the overall individual mean against the overall indi-
vidual mean both on the natural and log-transformed (on
base 10) basis. This procedure generated 1 data point by
subject by session thus yielding 234 data points (39 sub-
jects × 6 sessions = 234). The possible learning effect was
assessed by comparing the 6 successive sessions and the
morning sessions on day 1 and day 5 using a repeated
measure analysis of variance. In turn, the diurnal variation
was assessed by comparing, using a matched t-test, the
morning session vs. the afternoon session on day 5.
A multiple linear regression model was used to assess the
association between log-transformed FENO, taken as the
dependent variable, and other, independent variables
including age, height, sex, smoking habits and spirometric
variables.
A sample size determination was calculated to achieve an
80% power in a study in which FENO would be measured
twice e.g. before and after exposure to some risk factor.
The statistical test is based on the individual difference of
log-transformed values at time 2 and time 1 tested to beBMC Pulmonary Medicine 2008, 8:4 http://www.biomedcentral.com/1471-2466/8/4
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equal to zero by a standard two-sided Student test. In
other words, it tests an increase in percent of the initial
measurement. The expected standard deviation of this dif-
ference of (log-transformed) measurements is estimated
using the within-subject between-session standard devia-
tion of the log-transformed mean of the three measure-
ments which is assumed to be equal to the individual
long-term variability.
Results
FENO levels were measured on 702 occasions. The normal-
ity of the data was rejected (Shapiro-Wilk test, p <
0.0001), mainly because of 1 outlying subject, but not the
log-normality. Descriptive statistics by sex and smoking
habits are presented in Table 1. Smoking men were
slightly older and had greater cigarette consumption than
smoking women but the differences were not significant
(p values of 0.302 and 0.360, respectively). Among non-
smokers, women were older than men (p = 0.003). BMI
was within the normal range and comparable among the
four groups.
The overall within-session standard deviation was 1.78
parts per billion (ppb); males and non-smokers displayed
higher FENO levels and correspondingly higher standard
deviations. FENO values at each visit are presented by gen-
der and smoking status in Table 2. The geometric mean
FENO for male smokers (average = 15.8 ± 1.66) was 1.37
times higher than in female smokers (average = 11.5 ±
1.82). The mean FENO for male non-smokers (average =
33.1 ± 2.4) was 2.04 times higher than in female non-
smokers (average = 16.2 ± 1.51). Overall, FENO measure-
ments made at different visits were highly reproducible
throughout the study. There was no significant day-to-day
variation. Also, morning and afternoon values at visit 5
were close to each other showing no significant diurnal
variation. Finally, the repeated measure ANOVA shows
that  FENO  varies significantly over the week with a
decrease of about 12% between the two first measure-
ments and the others. However, it can be seen that among
non-smoking females this decrease is not constant. No
diurnal difference was noted comparing the last 2 ses-
sions.
Table 3 displays the coefficients of the multiple linear
regression model used to assess the association between
FENO and several independent variables. Gender, smok-
ing, height and the FEV1/FVC ratio expressed in percent
predicted, but not age, were significantly associated with
FENO. The estimated difference of -0.098 on the decimal
log scale between men and women, adjusted on the other
factors, corresponds to a predicted FENO value for men
which is multiplied by 100.098 = 1.25 or equivalently an
FENO  value among women which is 25% lower than
among men. Similarly the FENO among non-smokers is
69% larger than among smokers and it increases by 2.6%
by centimetre height and by 4% by %FEV1/FVC. The influ-
ence of age is negligible in this model and is far from sta-
tistical significance in any of the models considered. It is
to be noted (data not shown) that height was non-signif-
icant when the FEV1/FVC ratio was replaced by the FEV1 or
if the spirometric variables were omitted from the model.
Table 1: Baseline characteristics of participants. Values are mean (SD).
Parameter Smokers Non-Smokers
Men Women Men Women
Nb of subjects 99 1 0 1 1
Age, years 34.6 (9.9) 29.7 (9.6) 26.2 (2.0) 38.5 (11.3)
Height, cm 178.2 (8.4) 166.8 (3.2) 176.4 (7.0) 166.1 (5.4)
Weight, kg 73.8 (8.3) 64.6 (12.5) 73.8 (9.3) 63.2 (9.0)
BMI, kg/m2 23.2 (2.0) 23.2 (4.7) 23.7 (2.6) 22.9 (2.7)
Cigarettes, p.y 8.8 (12.1) 4.6 (5.7) 0 0
Years smoking 14.2 (9.6) 8.5 (5.1) - -
FEV1
L 3.86 (0.69) 2.93 (0.32) 3.97 (0.55) 2.83 (0.49)
% predicted 92.2% (11.1) 90.3% (7.4) 91.5% (10.5) 94.4% (8.9)
FVC
L 4.84 (0.81) 3.71 (0.48) 4.97 (0.63) 3.53 (0.58)
% predicted 96.2% (9.6) 99.8% (11.6) 96.8% (6.1) 101.6% (9.7)
FEV1/FVC
% observed 79.7(5.1) 79.2 (5.6) 80.1 (8.8) 80.4% (5.9)
Abbreviations:
BMI: Body mass index
p.y = pack years
FEV1: Forced expiratory volume in one second
FVC: Forced vital capacityBMC Pulmonary Medicine 2008, 8:4 http://www.biomedcentral.com/1471-2466/8/4
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When performing unadjusted univariate analyses, the
coefficients for smoking, age, height and FEV1/FVC were
very similar to the coefficients from the multiple model
and were all (except age) statistically significant. The
unadjusted gender difference (62%) is however much
larger than the adjusted one.
Bland-Altman analysis of distance from session means
using all 702 measurements yielded limits of agreement
of 3.56 ppb (i.e. 2 × SD or 1.78 × 2 = 3.56). Figure 1 shows
the within session repeatability of FENO for all recorded
measurements separately for smokers and non-smokers.
These figures show a variability which is similar among
smokers and non-smokers, for any given mean FENO
value.
In a longitudinal, long-term follow up study, only three
measurements will be taken at each time point corre-
sponding to a measurement session in the present series
of data so the individual parameters of interest are the
mean of the three measurements and its variance. This
variance can be estimated from our trial by computing the
variance of the 6 sessions. To compensate for the phe-
nomenon of heteroskedasticity (i.e; the variance increases
with the mean) – documented by a 0.89 correlation coef-
ficient between the subject-specific between session stand-
ard deviation and mean – we log-transformed FENO
values, yielding the log FENO (Figure 2). The variability is
much less dependent on the mean, the correlation coeffi-
cient between mean and standard deviation being now –
0.29.
Figure 3 represents the number of subjects necessary to
achieve an 80% power to detect a given (multiplicative)
increase in percent of the initially measured FENO level in
a second measure. The power calculations are based on an
estimated between-session within-subject standard devia-
tion of 0.078 corresponding to a geometric standard devi-
ation of 1.081. To achieve an 80% power to detect a mean
3% increase in exhaled NO, 111 subjects have to be
included. For a more clinically significant, say, 10% mean
increase, this number drops to 29.
Table 2: Geometrical mean (ppb) and geometrical SD of FENO measurement on six occasions in smokers and non-smokers stratified 
by gender.
Subjects Visit 1 Visit 2 Visit 3 Visit 4 Visit 5a Visit 5b Total
Smokers Men (n = 9) 17.8 (1.82) 15.8 (1.78) 15.1 (1.58) 15.8 (1.66) 14.8 (1.62) 16.2 (1.74) 15.8 (1.66)
Women (n = 9) 12.6 (2.00) 13.2 (2.09) 11.7 (1.78) 11.0 (1.82) 10.5 (1.86) 10.0 (1.62) 11.5 (1.82)
Non-smokers Men (n = 10) 33.9 (2.57) 36.3 (2.45) 30.9 (2.57) 32.4 (2.51) 32.4 (2.51) 32.4 (2.51) 33.1 (2.40)
Women (n = 10) 17.4 (1.78) 16.2 (1.51) 14.4 (1.51) 17.4 (1.41) 16.6 (1.51) 15.8 (1.48) 16.2 (1.51)
Visit 5a: 9:00 – 10:00 h
Visit 5b: 14:00 – 15:00 h.
Table 3: Multiple linear regression model with log-FENO as the dependent variable in relation to age, height, gender, smoking status 
and spirometry among 39 healthy subjects.
Variable Coefficient Std. Error t p [95% confidence interval]
Constant -2.13 0.641 -3.32 0.001 -3.394 -0.867
Age (year) 0.00003 0.002 -0.02 0.987 -0.003 0.003
Height (cm) 0.011 0.003 3.71 <0.001 0.005 0.017
Gender: Men vs. Women -0.098 0.046 -2.14 0.034 -0.188 -0.008
Smoker vs. Non-smoker -0.227 0.033 -6.94 <0.001 -0.292 -0.163
FEV1/FVC (% predicted) 0.017 0.002 7.40 <0.001 0.013 0.022
Within-session repeatability of FENO in smoking groups Figure 1
Within-session repeatability of FENO in smoking groups.BMC Pulmonary Medicine 2008, 8:4 http://www.biomedcentral.com/1471-2466/8/4
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Discussion
In this study, we demonstrate that FENO measurements are
reproducible, a finding consistent with results reported
previously in healthy subjects and patients with asthma
[4-7]. Yet, we provide new knowledge by showing that the
reproducibility of FENO is not influenced by gender nor
adversely affected by smoking status in smokers refraining
from smoking before testing. In addition, we show that
significant changes in FENO are potentially detectable with
fairly small numbers of subjects, an aspect of practical
importance when planning epidemiological studies.
However, it should be pointed out that our calculations
were based on the assumption that the variance of the
mean FENO measurement within the week in which the
essay was conducted represents the intrinsic long-term
variability of FENO in absence of any external factor influ-
encing it. Although this hypothesis seems reasonable – as
supported by the remarkable seasonal stability of FENO [7]
– only a much longer follow up of this measurement in a
similar population could validate it. Finally, it should be
stressed that this reasoning does not apply to managing
individual asthmatics in the clinical setting.
Our study differed from those quoted above [4-7] in three
ways. First, we examined males and females separately,
while some authors preferred to examine males only [5]
or merge males and females together [6,7]; one study did
not mention the subjects' gender [4]. Second, we exam-
ined smokers and non-smokers of both sexes separately,
while the above mentioned studies [4-6] did not take
smoking status into account. Finally, our series included
only healthy subjects while other series included asthmat-
ics as well [5,6].
For the sake of comparability, we used a protocol similar
to that of Kharitonov and colleagues [6]. The within-ses-
sion standard deviation was close to that noted by these
authors (1.8 ppb vs. 2.1 ppb) although it increased with
the mean FENO. However, in contrast to Kharitonov et al,
we did not exclude any a priori outliers as it would lead to
removing almost all measurements of subjects with high
FENO values. If such procedure were applied in any clinical
or epidemiological study it would imply removing the
most interesting subjects.
By plotting the distance between the session means and
the overall subject specific mean vs. the latter we showed
the within-subject between-session variance increased
with the subject mean; this feature disappeared when
using log-transformed measurements, which we would
therefore recommend as the relevant variable. This means
simply that any evolution of a subject's FENO is better
expressed in percent of the initial value rather than as an
increase or decrease in the absolute value.
The relationship between gender and FENO  has been
examined previously. Olin and colleagues [19] measured
FENO in a large random adult general population sample
(n = 2,200) and found that when both height and gender
were included in multiple regression model the contribu-
tion of gender was not significant. They postulated that
the alleged association FENO/male gender was probably
due to a height-dependent increase in the total airway
mucosal surface area that produces NO. However, con-
flicting results were published by others. Olivieri and col-
leagues [20] measured FENO  in 204 healthy, non-
smoking, non-atopic individuals and documented signif-
icantly higher FENO values in men compared with women.
Between-session repeatability of (log-transformed) FENO as  a function of subject's mean FENO level Figure 2
Between-session repeatability of (log-transformed) FENO as 
a function of subject's mean FENO level. The numbers corre-
spond to the session number (from 1 to 6).
Number of subjects necessary to achieve an 80% power to  detect a given increase in percent of the initially measured  FENO level in a second measure Figure 3
Number of subjects necessary to achieve an 80% power to 
detect a given increase in percent of the initially measured 
FENO level in a second measure.BMC Pulmonary Medicine 2008, 8:4 http://www.biomedcentral.com/1471-2466/8/4
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Travers and colleagues [21] examined subjects aged
between 25 and 75 years and found that sex, atopy and
smoking status affected FENO levels; they presented refer-
ence ranges adjusted for these factors. More recently,
Robin Taylor and colleagues [22] examined 895 adults
aged 32 and found that FENO levels were nearly 25% less
in females and suggested that reference values should be
stratified by sex. In the present study we also found that
women had significantly lower FENO than men and that
the association between FENO and gender remained signif-
icant when height was included in the regression model.
There is evidence that genetic factors might play a role on
the genesis of the reported gender-related differences in
FENO. Graserman and colleagues [23] studied NO and
genetic variants in NO synthases in 105 healthy non-
smoking and smoking subjects. They found FENO to be
significantly higher in males than females among both
non-smokers and smokers. More importantly, they noted
that healthy non-smoking females with greater number of
repeats in neuronal NO synthase had significantly lower
NO levels than did females with fewer numbers of repeats.
They concluded that variants in the neuronal NO synthase
gene contribute to the variability of airway NO concentra-
tions in healthy females. More recently, Lund and col-
leagues [24] examined 377 adult twins identified through
the Norwegian Twin Registry and showed that genetic
effects accounted for 60% of the variation in FENO. The
influence of genetic factors on our results is not known
and clearly more studies are necessary to clarify this issue.
Our study confirms the well-established association
between cigarette smoking and FENO levels [8-13]. The
mechanisms by which smoking reduces FENO  are not
completely understood. Several possibilities have been
proposed including (i) a reduction of the endogenous NO
synthesis by feedback inhibition due to the high concen-
trations of NO contained in the cigarette smoke [9](ii) an
inadequate supply of cofactors necessary for NO produc-
tion [25] and (iii) an increase in the breakdown of NO
[26]. Recently, Malinovschi and colleagues [10] examined
the effect of past, current and passive smoking on FENO in
a general population sample using flow-independent NO
exchange parameters. They found lower FENO levels in
current smokers and attributed this to reduced NO levels
in both the airways and alveoli. Conversely, Pietropaoli
and colleagues [27] measured FENO at different expiratory
flow rates in asymptomatic smokers and age-matched
non-smokers and concluded that the diminished NO
expired by smokers resulted from diminished NO produc-
tion by the tissues of the conducting airways and not by
the alveoli. Whatever the mechanism, there appears that
FENO levels decrease with increasing years smoked and
with recent smoking [13]. Had it been present in our
study, the latter factor could have produced variations in
FENO levels and adversely affected our reproducibility.
However, to prevent such possibility and achieve stability
we asked our subject to avoid smoking for 8 hours before
FENO measurements.
Atopy might have influenced baseline FENO levels of our
subjects [19,28,29] although we are not aware of such an
effect in absence of any airway inflammation. However,
while the NO level of atopic subjects can be expected to
increase specifically under the influence of a risk factor
[30], in absence of any such factor, there is no reason it
should vary considerably. Excluding atopic subjects in a
longitudinal study would thus bias the results of that
study towards the absence of effect. By consequence, we
decided not to screen our subjects for asymptomatic atopy
(e.g. by performing skin prick tests to common allergens)
nor eliminate outliers.
A final word must be said about our protocol. As with
other tests, FENO measurement may be influenced by tech-
nical and biological sources of variation. To deal with the
former, all measurements were carried out by the same
operator, using the same instrument – which met the ATS
criteria for precision and accuracy [14] – according to a
standardized procedure. Further, care was taken to ensure
the subjects' comprehension, comfort and cooperation
during the procedure. As for biological sources, we took
care to record carefully the subjects' recent exposures and
activities. In addition, we dealt with the possible role of
circadian rhythms by asking each subject to come to the
laboratory every day at the same hour. Incidentally, our
average FENO values were within the limits of reported ref-
erence values established using NO analyzers of the same
manufacturer [21,31]. For smokers, our values are below
both the upper limit of 36.4 ppb for females and the
upper limit of 45.9 ppb for males proposed by Travers and
colleagues [21]. For non-smokers, our values are similar
to the 31.2 ppb value predicted for men and below the
29.7 ppb value predicted for women by Olin and col-
leagues [31] and far below the upper limit of 44.6 and
56.5 ppb proposed respectively for women and men by
Travers and colleagues [21].
Conclusion
In summary, this study improves our understanding of
the reproducibility of FENO in two ways. First, it shows
that this reproducibility is not influenced by gender or
smoking status in subjects refraining from smoking before
FENO assessment. Second, it provides evidence that FENO
is potentially useful in the survey of populations, fairly
small samples being necessary to assess significant
changes in FENO levels. This finding could be of practical
importance for the survey of populations at risk of asthma
since traditional means of monitoring such as tests of lung
function and bronchial provocation tests are not directly
related to airway inflammation. Further studies, carried
out over longer periods of time, would be necessary toBMC Pulmonary Medicine 2008, 8:4 http://www.biomedcentral.com/1471-2466/8/4
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confirm the assumption that the short-term variance of
FENO represents its intrinsic long-term variability.
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